Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals. Pixantrone was specifically designed to have a higher affinity and avidity for the topisomerase II enzyme, which is the common target for this class of anti-cancer agents, while reducing oxygen-free radicals and preventing the formation of toxic drug metal complexes, which are the primary culprit that leads to dose-related irreversible heart damage associated with standard anthracyclines.

"This study adds to the growing scientific evidence which is central to the mechanistic basis for the relatively low incidence of cardiac events observed in our pixantrone clinical trials compared to the expected incidence of events had other anthracyclines been used. The ability to reintroduce an effective anthracycline like agent to patients who are no longer eligible to receive further standard anthracycline therapy due to potential irreversible heart damage addresses a major and growing unmet medical need," Jack Singer, M.D., Chief Medical Officer of Cell Therapeutics, Inc.

About the Study

To validate the proposed mechanisms underlying the observed differences in cardiotoxicity, researchers used established spectrophotometric techniques to quantify iron and drug interactions that are thought to be mechanistic for chronic doxorubicin cardiotoxicity. When adding increasing amounts of iron to drug solutions, they observed that doxorubicin and mitoxantrone underwent changes in visible range absorbance patterns, which is characteristic of the drug to iron complex formation, confirming the expected 1:3 Fe(II)-drug ratio for both doxorubicin and mitoxantrone. In contrast, no spectrophotometric changes were observed with iron added to pixantrone, clearly demonstrating that pixantrone does not bind iron. In vitro studies using H2C9 rat myocardial cells indicate that pixantrone (ID50 >50 ug/ml) is far less toxic than doxorubicin (ID50= 1 ug/ml). Moreover, pixantrone does not induce significant reactive oxygen species (ROS) production in the H2C9 cells compared to doxorubicin.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status designation.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, the potential failure of pixantrone to significantly reduce cardiac cell toxicity compared to currently marketed anthracyclines, the potential failure of pixantrone to reintroduce an effective anthracycline like agent in patients, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com

SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
(Date:4/28/2016)... 2016 Treato , the ... announced today that it has been named a Cool ... in Life Sciences, 2016, Stephen Davies , ... focuses on life-science- oriented analytics, algorithms and smart machine ... doctors, confirm medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... 28, 2016   Acsis , a leading provider ... IT market research and advisory firm IDC has named ... MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 Vendor ... an assessment of the capabilities and business strategies of ... market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... ... Excessive panting in the car or cowering when new guests arrive are ... only manifests itself as trembling or ‘tail between the legs,’ but a pet ... about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn pet health products ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a leader ... Health, a three hospital system in South Carolina, to provide its secure mobile ... technology that enhances communication, drives workflow efficiencies and improves provider and patient satisfaction,” ...
(Date:5/3/2016)... ... , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) Center ... rare procedures in an environment that looks and feels real. , Located in the ... and “hackers” to develop and test new devices or software platforms and see how ...
(Date:5/3/2016)... ... ... Each year, about 800,000 people suffer from cerebral vascular accidents, or strokes. ... one death every four minutes. Many people who survive a stroke are left ... video series called “Your Brain,” in conjunction with its medical journal “Balance,” in order ...
(Date:5/3/2016)... ... 2016 , ... Ogawa World USA introduced the first of its kind ... Smart Application. The Smart 3D combines the best in technological advancement, design, and massage ... and specialized massage program, each user has a tailored experience unparalleled by any other ...
Breaking Medicine News(10 mins):